T-Cell Prolymphocytic Leukemia
(2024) p.3-662- Abstract
This chapter summarizes current knowledge and diagnostic criteria for T-cell prolymphocytic leukemia (T-PLL). T-PLL is an aggressive disease characterized by a proliferation of small to medium-sized lymphocytes with a postthymic phenotype usually involving the blood, bone marrow, lymph nodes, spleen, and skin. The leukemic cells are usually positive for CD2, CD3 CD5, CD7, CD43, CD52, and CD26, but CD4 and CD8 are variably expressed. T-PLL is diagnosed by the presence of three major criteria (>5 × 109/L cells of T-PLL phenotype in peripheral blood or bone marrow, T-cell clonality, abnormalities of 14q32 or Xq28 OR expression of TCL1A/B or MTCP1) or two major criteria and one of the minor criteria: abnormalities involving chromosome 11... (More)
This chapter summarizes current knowledge and diagnostic criteria for T-cell prolymphocytic leukemia (T-PLL). T-PLL is an aggressive disease characterized by a proliferation of small to medium-sized lymphocytes with a postthymic phenotype usually involving the blood, bone marrow, lymph nodes, spleen, and skin. The leukemic cells are usually positive for CD2, CD3 CD5, CD7, CD43, CD52, and CD26, but CD4 and CD8 are variably expressed. T-PLL is diagnosed by the presence of three major criteria (>5 × 109/L cells of T-PLL phenotype in peripheral blood or bone marrow, T-cell clonality, abnormalities of 14q32 or Xq28 OR expression of TCL1A/B or MTCP1) or two major criteria and one of the minor criteria: abnormalities involving chromosome 11 (11q22.3, ATM); abnormalities in chromosome 8, including idic(8)(p11), t(8;8), and trisomy 8q; abnormalities in chromosomes 5, 12, 13, or 22 or in complex karyotype; or involvement of T-PLL-specific site (e.g., splenomegaly, effusions).
(Less)
- author
- Porwit, Anna LU
- organization
- publishing date
- 2024-01-01
- type
- Chapter in Book/Report/Conference proceeding
- publication status
- published
- subject
- keywords
- bone marrow biopsy, cytology, immunophenotyping, leukemia, prolymphocytic, T-cell
- host publication
- Hematopathology, 3rd Edition
- pages
- 3 - 662
- publisher
- Elsevier
- external identifiers
-
- scopus:105011420998
- ISBN
- 9780323831659
- 9780323831666
- DOI
- 10.1016/B978-0-323-83165-9.00031-5
- language
- English
- LU publication?
- yes
- additional info
- Publisher Copyright: © 2025 Elsevier Inc. All rights reserved.
- id
- 810a3cf0-ef88-414a-a7c3-b1e7e624e088
- date added to LUP
- 2026-02-05 14:43:44
- date last changed
- 2026-06-26 08:46:19
@inbook{810a3cf0-ef88-414a-a7c3-b1e7e624e088,
abstract = {{<p>This chapter summarizes current knowledge and diagnostic criteria for T-cell prolymphocytic leukemia (T-PLL). T-PLL is an aggressive disease characterized by a proliferation of small to medium-sized lymphocytes with a postthymic phenotype usually involving the blood, bone marrow, lymph nodes, spleen, and skin. The leukemic cells are usually positive for CD2, CD3 CD5, CD7, CD43, CD52, and CD26, but CD4 and CD8 are variably expressed. T-PLL is diagnosed by the presence of three major criteria (>5 × 109/L cells of T-PLL phenotype in peripheral blood or bone marrow, T-cell clonality, abnormalities of 14q32 or Xq28 OR expression of TCL1A/B or MTCP1) or two major criteria and one of the minor criteria: abnormalities involving chromosome 11 (11q22.3, ATM); abnormalities in chromosome 8, including idic(8)(p11), t(8;8), and trisomy 8q; abnormalities in chromosomes 5, 12, 13, or 22 or in complex karyotype; or involvement of T-PLL-specific site (e.g., splenomegaly, effusions).</p>}},
author = {{Porwit, Anna}},
booktitle = {{Hematopathology, 3rd Edition}},
isbn = {{9780323831659}},
keywords = {{bone marrow biopsy; cytology; immunophenotyping; leukemia; prolymphocytic; T-cell}},
language = {{eng}},
month = {{01}},
pages = {{3--662}},
publisher = {{Elsevier}},
title = {{T-Cell Prolymphocytic Leukemia}},
url = {{http://dx.doi.org/10.1016/B978-0-323-83165-9.00031-5}},
doi = {{10.1016/B978-0-323-83165-9.00031-5}},
year = {{2024}},
}